RxDoctor Payments Data

Shelby McGee

Nurse Practitioner · Asheboro, NCNPI 1386003135

Payments from drug & device makers

$922in general payments, 2019–2025

Across 36 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$542
  • AbbVie$195
  • Lilly USA, LLC$77
  • Boehringer Ingelheim$56
  • Exact Sciences$14
  • Redhill Biopharma Inc.$13
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$922 in reported general payments places this provider in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$264
Medicare patients
15
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$85,469
MounjaroTirzepatide40$56,710
FarxigaDapagliflozin Propanediol45$52,762
JardianceEmpagliflozin41$51,415
RybelsusSemaglutide11$24,356
XareltoRivaroxaban22$15,908
JanuviaSitagliptin Phosphate18$14,671
SymbicortBudesonide/Formoterol Fumarate27$9,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,551
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,101
Sumatriptan11$2,871
Diclofenac Sodium32$2,257
Gabapentin101$2,238
Albuterol Sulfate HfaAlbuterol Sulfate80$2,182
Omeprazole86$1,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$12$109,82662 claims
AstraZenecaFarxiga, Symbicort$542$62,38472 claims
Lilly USA, LLCMounjaro$77$56,71040 claims
Boehringer IngelheimJardiance$56$51,41541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →